Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 31st Preview)
-
FDA approvals in rare blood disorders
Takeda won FDA approval for Mimrylo (rusfertide) in polycythemia vera, with the engineered peptide originally developed by Protagonist Therapeutics. The approval follows a label broader than some analysts expected and opens a new, repeatable revenue opportunity for Takeda as parts of its pipeline shift toward hematology. The decision also marks a key milestone for Protagonist, which previously secured approvals earlier in the year. Under the partnership model, Takeda is positioned to commercialize Mimrylo across the adult PV population while Protagonist retains scientific momentum from a second approval cycle. Separately, FDA cleared Mimrylo specifically for erythrocytosis in adults with PV, confirming an anticipated weekly-injection regimen and reinforcing the therapy’s role as a targeted hepcidin-mimetic approach in a disease area with limited options.
-
Dealmaking and corporate strategy—Lilly acquires Merida Biosciences
Eli Lilly agreed to buy Merida Biosciences for $2.875 billion, betting on a more selective immunology approach focused on degrading pathogenic autoantibodies. The deal adds Merida’s Graves disease program and technology for antibody targeting to Lilly’s growing immunology portfolio. Lilly’s acquisition is structured with an upfront component and contingent milestones, with analysts previously framing Merida as a potential contributor to a sizable commercial opportunity if clinical execution matches expectations. Lilly is positioning Merida’s lead asset, MER511, as a course-changing alternative for autoimmune disease—designed to eliminate targeted disease-causing antibodies rather than broadly suppress immunity. The transaction continues Lilly’s unusually active 2026 acquisition pace, extending prior immunology buyouts and strengthening its pipeline beyond obesity and diabetes.
-
Regulatory litigation over GLP-1 drug shortages
A U.S. Court of Appeals panel upheld a lower-court ruling blocking compounders’ challenges to the FDA’s removal of Eli Lilly and Novo Nordisk GLP-1 drugs from the agency’s shortage list. The court effectively sidestepped whether FDA removal requires a notice-and-comment rulemaking after determining the shortage has ended. The decision maintains the FDA’s ability to update shortage status without extended procedural steps, a practical issue for manufacturing entities relying on shortage designations and for patients affected by supply constraints. For biopharma stakeholders, the ruling narrows the legal path for parties arguing that FDA shortage-list changes demand full rulemaking, keeping the current regulatory mechanics intact.
-
Government drug pricing commitments with MFN-style offers
The White House announced nine additional “most-favored nation”-style voluntary pricing deals with drugmakers, adding companies including Alcon, Astellas, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB to a growing list of signatories. The administration said the deals are intended to lower prices and help avoid tariffs tied to CMS pilot programs under review. The terms described by the administration mirror earlier agreements: sell new medications to U.S. patients at prices comparable to the lowest in peer countries, offer drugs to Medicaid programs at MFN prices, and in some cases support domestic manufacturing and U.S. medical stockpiles. For manufacturers, the announcements extend a fast-moving policy environment where commercial strategy is increasingly intertwined with federal pricing frameworks and tariff risk.
-
Clinical access impact after Medicare negotiated-price rollout
New IQVIA analysis reports that Medicare drug price cuts tied to the 2026 negotiation program did not automatically translate into patient access. In the first quarter of 2026, nearly a quarter of patients attempting to fill prescriptions faced initial rejections, including high rejection rates for immunology and oncology drugs. The data looked at the first 10 negotiated drugs after maximum fair prices took effect on January 1, 2026, while noting that Part D formularies include the medications even when coverage does not guarantee access. Prior authorization, step therapy, and other utilization management tools appear to continue blocking timely fills. The report recommends ongoing monitoring of patient access metrics—not only government savings—highlighting how access barriers at the pharmacy counter can persist even under headline pricing reforms.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.